Facundo Salinas

Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies

H. Ortega, F. Goldbaum, V. Zylberman, 2021, Toxicology and Applied Pharmacology.

New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis

A. F. Castillo, D. Gomez, P. Maloberti, 2020, Cellular and Molecular Life Sciences.

Development and biological evaluation of pNIPAM-based nanogels as vaccine carriers.

F. Alustiza, O. Taboga, M. Molina, 2022, International journal of pharmaceutics.

[Development and validation of analytical techniques for the determination of blood biomarkers in preclinical trials. Why and what for?]

H. Ortega, G. Hein, A. Stassi, 2021, Medicina.